Golden State Medical Supply Inc.

Complete recall history across all FDA and CPSC categories — 50 total recalls

Golden State Medical Supply Inc. appears in recall records across 1 category. This page consolidates all FDA food, drug, and medical device enforcement actions, plus CPSC consumer product recalls associated with this company. Recall data is sourced from openFDA and CPSC public databases.

Drug Recalls (50)

FDA drug safety enforcement actions by Golden State Medical Supply Inc.

Date Product Reason Class
Apr 27, 2026 Primidone Tablets, USP, 250 mg, 100-count bottle, RX only, Manufactured by: L... Cross contamination with other products: API contaminated with trace amounts ... Class III
Apr 27, 2026 Primidone Tablets, USP, 50 mg, 50-count bottle, RX only, Manufactured by: Lan... Cross contamination with other products: API contaminated with trace amounts ... Class III
Nov 26, 2025 Baclofen Tablets USP, 10 mg, 1000-count bottles, Rx only, Marketed by: GSMS, ... Presence of Foreign Tablets/Capsules Class II
Oct 20, 2025 NIACIN Extended-Release Tablets, USP, 1,000 mg, 90 tablets per bottle, Rx onl... Failed Dissolution Specifications Class II
Mar 5, 2025 PRASUGREL TABLETS, 5 mg, 30 tablet bottles, Rx only, packaged by GSMS, Incorp... Failed Dissolution Specifications Class II
May 13, 2024 Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottl... CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDS... Class II
Feb 14, 2024 Fluticasone Propionate Nasal Spray USP, 50 mcg per spray, 120 metered sprays,... CGMP Deviations:Suspected potential presence of Burkholderia cepacia complex Class II
Jan 12, 2024 Budesonide Extended-Release Tablets, 9 mg, 30-count bottles, Rx only, Markete... Failed Dissolution Specifications Class II
Nov 10, 2023 PAROXETINE tablets, USP, 20 mg, Packaged as a) 90-count bottle NDC 60429-735-... Failed Impurities/Degradation Specifications-Manufacturer Apotex Inc. recalli... Class II
Nov 10, 2023 PAROXETINE tablets, USP, 40 mg, Packaged as a) 30-count bottle, NDC 60429-73... Failed Impurities/Degradation Specifications-Manufacturer Apotex Inc. recalli... Class II
Nov 10, 2023 PAROXETINE tablets, USP, 10 mg, Packaged as a) 30-count bottle, NDC 60429-73... Failed Impurities/Degradation Specifications-Manufacturer Apotex Inc. recalli... Class II
May 25, 2023 Travoprost Ophthalmic Solution, USP (Ionic Buffered Solution), 0.004%, Rx onl... Lack of Assurance of Sterility: Tamper Evidence Seal is missing on secondary ... Class II
Oct 6, 2022 Rifampin Capsules, USP, 300 mg, packaged in a) 30-count bottle (NDC 51407-323... Failed impurities/degradation specifications: Finished product exceeds the 5 ... Class II
Oct 6, 2022 Rifampin Capsules, USP, 150 mg, 30-count bottle, Rx only, Manufactured by Pat... Failed impurities/degradation specifications: Finished product exceeds the 5 ... Class II
Sep 29, 2022 Atenolol Tablets, USP, 25 mg, 1000-count bottle, Rx only, Manufactured by: AL... Label Mix - up; a bottle labeled as Atenolol 25mg Tablets contained Clopidogr... Class I
Mar 16, 2022 Enalapril Maleate Tablets, USP; 20 mg; 90 tablets, NDC 60429-186-90; manufact... CGMP Deviations Class II
Mar 16, 2022 Enalapril Maleate Tablets, USP; 5 mg; 90 tablets, NDC 60429-184-90; manufactu... CGMP Deviations Class II
Mar 16, 2022 Enalapril Maleate Tablets, USP; 10 mg; 90 tablets, NDC 60429-185-90; manufact... CGMP Deviations Class II
Mar 16, 2022 Enalapril Maleate Tablets, USP; 2.5 mg; 90 tablets, NDC 60429-183-90; manufac... CGMP Deviations Class II
Mar 2, 2022 Alprazolam Tablets, USP 1mg, 180-count bottles, Rx only, Manufactured by ULTR... CGMP Deviation: Potential cross-contamination with other drug substance durin... Class II
Oct 14, 2021 Ezetimibe and Simvastatin Tablets, 10 mg/80mg, 500 tablet bottles, Rx only, M... Failed Excipient Specification; product manufactured using an excipient found... Class II
Oct 14, 2021 Ezetimibe and Simvastatin Tablets, 10 mg/40mg, a) 90 Tablets, b) 500 tablets,... Failed Excipient Specifications and Presence of Foreign Tablets/Capsules; pro... Class II
Mar 19, 2021 Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only,... Failed Impurities/Degradation Specifications: Out of Specification results ob... Class II
Nov 17, 2020 ARIPIPRAZOLE TABLETS, 15 mg, 30-count. bottles, Rx Only, GSMS Incorporated, M... FAILED DISSOLUTION SPECIFICATIONS: Possibility of out-of-specification (OOS) ... Class II
Jul 24, 2020 Clobetasol Propionate Cream, USP, 0.05%, packaged in a)15g Tubes (NDC 60429-9... Failed Content Uniformity: bulk lot used to make these two lots was found to ... Class III
Apr 3, 2020 Losartan Potassium Tablets, USP, 25 mg, Rx only, a) 30 ct. (NDC 60429-316-30)... CGMP Deviations: Impurity for N-nitroso-N-methyl-4-aminobutryric Acid (NBMA) ... Class II
Feb 12, 2020 TRAMADOL HYDROCHLORIDE Tablets, USP, 50 mg, Rx Only a)100-count bottles (NDC ... Labeling: Incorrect package insert - Patient leaflets for the specified lots ... Class III
Nov 6, 2019 GSMS: Ranitidine Capsules 300 mg, Rx only, 100 count bottles (NDC 51407-098-0... CGMP Deviations: Presence of NDMA impurity detected in product. Class II
Nov 6, 2019 GSMS: Ranitidine Capsules 150 mg, Rx only, 500 count bottles (NDC 51407-097-0... CGMP Deviations: Presence of NDMA impurity detected in product. Class II
Jun 14, 2019 Losartan Potassium, 50 mg tablets, 90 count bottle, NDC 60429-317-90 CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) d... Class II
Jun 14, 2019 Losartan Potassium, 100 mg tablets, 90 count bottle, NDC 60429-318-90 CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) d... Class II
Jun 14, 2019 Losartan Potassium, 50 mg tablets, 30 count bottle, NDC 60429-317-30 CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) d... Class II
Jun 14, 2019 Losartan Potassium, 50 mg tablets, 1000 count bottle, NDC 60429-317-10 CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) d... Class II
May 1, 2019 Losartan Potassium Tablets USP 25 mg 90 count bottle NDC 60429-316-90 Rx only... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... Class II
May 1, 2019 Losartan Potassium Tablets USP 100 mg 90 count bottle NDC 60429-318-90 Rx onl... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... Class II
May 1, 2019 Losartan Potassium Tablets USP 100 mg 1000 count bottle NDC 60429-318-10 Rx o... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... Class II
May 1, 2019 Losartan Potassium Tablets USP 25 mg 1000 count bottle NDC 60429-316-10 Rx on... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... Class II
May 1, 2019 Losartan Potassium Tablets USP 25 mg 30 count bottle NDC 60429-316-30 Rx only... CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... Class II
Nov 2, 2018 IRBESARTAN Tablets, USP 75 mg 90-count bottle, Rx Only, Manufactured by: SciG... CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-... Class II
Nov 2, 2018 IRBESARTAN Tablets, USP 150 mg (a) 30-count bottle (NDC 60429-641-30), (b) 90... CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-... Class II
Nov 2, 2018 IRBESARTAN Tablets, USP 300 mg (a) 30-count bottle (NDC 60429-642-30), (b) 90... CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-... Class II
Aug 3, 2016 Venlafaxine Hydrochloride Extended-Release Capsules, 75 mg, 90 capsules per ... Failed Dissolution Specifications: Out-of-specification results in retained s... Class II
Aug 3, 2016 Venlafaxine Hydrochloride Extended-Release Capsules, 150 mg, a) 30 capsules p... Failed Dissolution Specifications: Out-of-specification results in retained s... Class II
Jun 28, 2016 DULOXETINE Delayed-Release Capsules, USP, 60 mg, 1000 count bottles, Rx only,... Labeling; Incorrect or Missing Lot and/or Exp Date; incorrect expiration date... Class III
Jan 27, 2016 Atorvastatin Calcium 80 mg, 10 tablets per blister,100-count package, Rx Only... Failed Impurities/Degradation Specifications Class III
Jan 27, 2016 Atorvastatin Calcium 20 mg, 10 tablets per blister,100-count package, Rx Only... Failed Impurities/Degradation Specifications Class III
Jan 27, 2016 Atorvastatin Calcium 10 mg, 10 tablets per blister,100-count package, Rx Only... Failed Impurities/Degradation Specifications Class III
Jan 27, 2016 Atorvastatin Calcium 40 mg, 10 tablets per blister,100-count package, Rx Only... Failed Impurities/Degradation Specifications Class III
Nov 25, 2015 MECLIZINE HYDROCHLORIDE TABLETS, 12.5 mg, Packaged in 1000 ct Bottles, Rx Onl... Failed Impurities/Degradation Specifications: Out of specification for impuri... Class III
Nov 25, 2015 MECLIZINE HYDROCHLORIDE TABLETS, 25 mg, Packaged in a) 100 ct Bottles (NDC: 6... Failed Impurities/Degradation Specifications: Out of specification for impuri... Class III

Frequently Asked Questions

A high number of recalls does not necessarily indicate that a company is unsafe. Large manufacturers that produce thousands of products across multiple categories will statistically appear in recall databases more frequently. What matters more is the severity of each recall (Class I being the most serious), the speed of response, and whether the company proactively identified and addressed the issue. Companies with robust safety programs often catch problems earlier.

Food, drug, and medical device recall data comes from the FDA's openFDA enforcement database, which contains all FDA enforcement reports. Consumer product recall data comes from the U.S. Consumer Product Safety Commission (CPSC). Both sources are public government databases that are updated regularly. RecallCheck aggregates these sources to provide a unified view of a company's recall history.

The FDA classifies recalls into three categories. Class I is the most serious — there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. Class II means the product may cause temporary or medically reversible health problems, or the probability of serious consequences is remote. Class III is the least serious — the product is unlikely to cause adverse health consequences. CPSC product recalls do not use this classification system.

Yes. You can search for any company using the firm/manufacturer pages for each category: Food Firms, Drug Firms, Device Firms, or Product Manufacturers. You can also use the search functionality on any browse page to find recalls by company name.

Explore More Recalls

Search recalls by category, state, reason, or firm across all our databases.